Finasteride Cuts Prostate Cancer Risk Long Term


The Finasteride, a common treatment for prostate enlargement, results in a significantly lower risk of prostate cancer (PCa) long after the medication is discontinued, researchers recently concluded.

The finding extends the results of the Prostate Cancer Prevention Trial (PCPT), which demonstrated that 7 years of finasteride treatment decreased the risk of Prostate Cancer by 25% compared with placebo among men aged 55 years and older. Whether this risk-lowering effect of finasteride is maintained after discontinuing the drug has been unclear.

The beneficial effect was most pronounced in the first 7.5 years (29% reduction in Prostate Cancer risk), consistent with original PCPT findings, Dr Unger's team reported. After 7.5 years, the investigators observed no increased risk of PCa among finasteride recipients.


Unger JM, Hershman DL, Till C, et al. Using Medicare claims to examine long-term prostate cancer risk of finasteride in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2018; DOI: 10.1093/jnci/djy035

Send me a message if you have any question or make an appointment (toll-free: 800444444 or +971 4 520 0500)

Emirates Hospital, Jumeirah Beach Road, opposite Jumeirah Park (below the Dubai Canal Bridge Take the U-turn under the bridge to reach the entrance) - Dubai